newsfilter
← Latest News
GlobeNewswire·

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity